Surgery for Recurrent Intrahepatic Cholangiocarcinoma

The investigators retrospectively reviewed the participants suffering from recurrent intrahepatic cholangiocarcinoma after curative resection and aimed to explore the predictive factors for recurrence and clarify the potential benefit of repeat hepatectomy or/with metastasectomy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cholangiocarcinoma, Intrahepatic Adenocarcinoma Carcinoma Cholangiocarcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Re-hepatectomy Recurrence Cholangiocarcinoma

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Chang Gung Memorial Hospital Linkou Branch

Taoyuan, 333, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

R0 resection for intrahepatic cholangiocarcinoma at initial diagnosis.

Exclusion criteria

(1)Patient with R1 or R2 resection
(2)Distant metastasis noted when laparotomy
(3)Surgical mortality

Treatment and study plan

Hepatectomy

Procedure

Hepatectomy for patients with recurrent intrahepatic cholanigocarcinoma

Primary outcomes

Survival

Time frame: 1977~2014

Including overall survival and disease free survival

Sponsors and collaborators

Lead sponsor

Chang Gung Memorial Hospital

Other

Registry information

Official study title

Surgery for Recurrent Intrahepatic Cholangiocarcinoma: a Promise or an Excess?

Important dates

Study start: 2017
Primary completion: 2018
Study completion: 2018
First posted: Aug 28, 2019
Registry last updated: Sep 13, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed